Biopharma Daily Stock Updates - 01/28/21

$XBI $151.64 (-0.43%)

COVID:

$NVAX (+2.16%) - Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial

$RDHL (+1.38%) - RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals

PIPELINE:

$AXSM (+0.97%) - Remains on track and is in the process of submitting a New Drug Application (“NDA”) for AXS-05 in major depressive disorder, expected imminently.

$AYLA (-4.93%) - Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer

$NK (-5.97%) - ImmunityBio Announces Positive Phase 2 Results Showing that Anktiva Restores the Activity of Checkpoint Inhibitors in Patients Who Have Relapsed Checkpoint Immunotherapy in Non-Small Cell Lung Cancer

$PHAS (-3.86%) - Dosing of First Patient in European Union as Part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor

$PRVB (+3.77%) - Announces Key Findings from Pre-clinical Proof-of-concept Study for PRV-3279 for the Prevention of Immunogenicity of Gene Therapy

$TRVN (-0.45%) - Publication Highlighting OLINVYK™ Respiratory Safety Data in High-Risk Patients in Pain & Therapy

FINANCIAL:

$AGTC (-11.24%) - AGTC Announces Pricing of Public Offering of Common Stock and Warrants